Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Confidence Interval
100%
Real-world Outcomes
100%
Median Overall Survival
75%
Non-squamous
75%
Clinical Trials
50%
Tumor
50%
Monotherapy
50%
Chemotherapy
50%
Non-squamous Non-small Cell Lung Cancer
50%
Programmed Death-ligand 1 Expression
50%
Immunotherapy Therapy
50%
Histology
25%
United States
25%
Improved Outcomes
25%
Non-small Cell Lung Cancer (NSCLC)
25%
Long-term Efficacy
25%
Advanced Stage
25%
Pivotal Trial
25%
Combination Immunotherapy
25%
Healthcare Database
25%
Overall Survival
25%
Low Expression
25%
Survival Estimation
25%
Treatment Initiation
25%
Survival Outcomes
25%
Flatiron Health
25%
Real-world Progression-free Survival
25%
Overall Survival Benefit
25%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Immunotherapy
100%
Overall Survival
62%
Chemotherapy
37%
Clinical Trial
37%
Disease
25%
Neoplasm
25%
Monotherapy
25%
Programmed Death 1 Ligand 1
25%
Progression Free Survival
12%
Survival Estimate
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Immunotherapy
100%
Overall Survival
62%
Clinical Trial
37%
Chemotherapy
37%
Programmed Death 1 Ligand 1
25%
Disease
25%
Neoplasm
25%
Monotherapy
25%
Progression Free Survival
12%